Retrophin Inc (RTRX) 13.92 $RTRX
Retrophin to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 4:00PM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer of Retrophin, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City on Wednesday, February 11 at 2:40 p.m. ET.
RTRX: 13.92 (+0.44)
Retrophin Announces Voting Results of Special Meeting of Stockholders
Business Wire - Tue Feb 03, 4:30PM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that at a Special Meeting of Stockholders held earlier today, the Company's stockholders voted to approve a proposal ratifying the prior issuance of stock options to purchase 1,928,000 shares of common stock and 230,000 restricted shares of common stock granted to employees between February 24, 2014 and August 18, 2014. Approximately 99.3% of votes present in person or by proxy at the meeting were cast in favor of the proposal.
RTRX: 13.92 (+0.44)
Podcast: Why the biotech boom is still in the 1st inning
ESTMZ - Wed Jan 28, 12:55PM CST
In the latest episode of our weekly podcast, This Week on Estimize , our CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights . Joe tells us why he believes the biotech boom still has plenty...
BDSI: 14.92 (+0.93), GILD: 101.90 (+1.10), RTRX: 13.92 (+0.44), ASPX: 65.76 (+2.76)
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 23, 12:32PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LGCY: 13.35 (+0.51), QADB: 17.59 (+0.05), EOPN: 8.55 (-0.01), QADA: 20.36 (+0.14), IMKTA: 42.26 (-0.18), CHUY: 22.04 (-0.35), OTIC: 31.14 (+0.13), SNMX: 5.92 (+0.26), DWCH: 6.26 (-0.18), EGLT: 10.60 (+0.58), RTRX: 13.92 (+0.44), INFN: 17.56 (-0.10), Z: 106.50 (+1.75)
Retrophin provides 2014 revenue guidance
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 8:53AM CST
RTRX: 13.92 (+0.44)
Retrophin Announces Acquisition of Exclusive Right to Purchase Cholic Acid from Asklepion Pharmaceuticals
Business Wire - Mon Jan 12, 7:02AM CST
Retrophin, Inc. (NASDAQ:RTRX) and Asklepion Pharmaceuticals, LLC, a privately held rare disease pharmaceutical development company, today announced the signing of a definitive agreement under which Retrophin has acquired the exclusive right to purchase from Asklepion, all worldwide rights, titles, and ownership of cholic acid for the treatment of bile acid synthesis defects, if approved by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, Retrophin will pay Asklepion an upfront payment of $5 million and up to $73 million in milestones based on approval and net product sales, plus tiered royalties on future net sales of cholic acid. Retrophin has secured a line of credit from current lenders to cover necessary payments.
RTRX: 13.92 (+0.44)
Ligand wins US FDA's orphan drug designation for Sparsentan for focal segmental glomerulosclerosis
M2 - Mon Jan 12, 6:28AM CST
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) disclosed on Friday the receipt of orphan drug designation for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).
RTRX: 13.92 (+0.44), LGND: 55.91 (-0.35)
The Shuman Law Firm Investigates Retrophin, Inc.
Business Wire - Fri Jan 09, 7:00PM CST
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Retrophin, Inc. ("Retrophin" or the "Company"
(Nasdaq: RTRX). Retrophin is a New York, NY-based company that develops therapies for the treatment of serious, catastrophic or rare diseases.
RTRX: 13.92 (+0.44)
Ryan & Maniskas, LLP Announces Investigation of Retrophin, Inc.
PR Newswire - Fri Jan 09, 6:35PM CST
Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Retrophin, Inc. ("Retrophin" or the "Company" (NASDAQ: RTRX).
RTRX: 13.92 (+0.44)
Sparsentan tagged an Orphan Drug for rare nephropathy
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 9:47AM CST
RTRX: 13.92 (+0.44), LGND: 55.91 (-0.35)
Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
Business Wire - Fri Jan 09, 9:15AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Retrophin, Inc. (NASDAQ:RTRX) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).
RTRX: 13.92 (+0.44), LGND: 55.91 (-0.35)
Retrophin Provides Corporate Update
Business Wire - Fri Jan 09, 7:00AM CST
--Sparsentan for the treatment of FSGS receives orphan drug designation from FDA
RTRX: 13.92 (+0.44)
Updated: Harwood Feffer LLP Announces Investigation of Retrophin, Inc.
PR Newswire - Thu Jan 08, 7:10PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Retrophin, Inc. ("Retrophin" or the "Company" (NASDAQ: RTRX), concerning whether the board has breached its fiduciary duties to shareholders.
RTRX: 13.92 (+0.44)
Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Jan 06, 4:00PM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced the grant of inducement awards to 14 employees that occurred on January 5, 2015. The awards were granted as an inducement material to each such employee's entering into employment with Retrophin pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The 14 employees were granted inducement awards consisting of stock options to purchase an aggregate of 355,000 shares of Retrophin common stock and 40,000 shares of restricted common stock. The stock options and restricted common stock vest in equal quarterly installments over a period of three years. The stock options are nonstatutory stock options and have an exercise price equal to $13.02 per share, the fair market value of Retrophin's common stock on the date of grant.
RTRX: 13.92 (+0.44)
Commit To Buy Retrophin At $10, Earn 28.9% Annualized Using Options
StockOptionsChannel.com - Wed Dec 24, 11:18AM CST
Investors considering a purchase of Retrophin, Inc. shares, but cautious about paying the going market price of $12.82/share, might benefit from considering selling puts among the alternative strategies at their disposal.
RTRX: 13.92 (+0.44)
Attention Retrophin, Inc. (RTRX) Shareholders: Retrophin Mislead Investors According to a Newly Filed Class Action
GlobeNewswire - Mon Dec 22, 7:18PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Retrophin, Inc. (Nasdaq:RTRX) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between November 13, 2013 and September 30, 2014. Retrophin is a biopharmaceutical company that develops, acquires, and commercializes therapies for the treatment of serious, catastrophic, and rare diseases.
RTRX: 13.92 (+0.44)
The Winners for Best and Worst Biotech CEOs of 2014 Are...
at The Street - Thu Dec 18, 9:01AM CST
Congrats to David Schenkhein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
BLUE: 90.70 (+0.93), RTRX: 13.92 (+0.44), AGIO: 118.55 (+0.11)
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Retrophin, Inc. and a Lead Plaintiff Deadline of December 19, 2014 -- RTRX
GlobeNewswire - Tue Dec 16, 3:54PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Retrophin, Inc. ("Retrophin" or the "Company" (Nasdaq:RTRX) securities between March 27, 2014 and September 30, 2014.
RTRX: 13.92 (+0.44)
Retrophin Announces Addition to the NASDAQ Biotechnology Index
Business Wire - Tue Dec 16, 7:00AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to market open on Monday, December 22, 2014.
RTRX: 13.92 (+0.44)
Retrophin to Present at the 2015 Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 4:00PM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer of Retrophin, will be presenting at the 2015 Leerink Global Healthcare Conference in New York City on Wednesday, February 11 at 2:40 p.m. ET.
RTRX: 13.92 (+0.44)
Retrophin Announces Voting Results of Special Meeting of Stockholders
Business Wire - Tue Feb 03, 4:30PM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that at a Special Meeting of Stockholders held earlier today, the Company's stockholders voted to approve a proposal ratifying the prior issuance of stock options to purchase 1,928,000 shares of common stock and 230,000 restricted shares of common stock granted to employees between February 24, 2014 and August 18, 2014. Approximately 99.3% of votes present in person or by proxy at the meeting were cast in favor of the proposal.
RTRX: 13.92 (+0.44)
Podcast: Why the biotech boom is still in the 1st inning
ESTMZ - Wed Jan 28, 12:55PM CST
In the latest episode of our weekly podcast, This Week on Estimize , our CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights . Joe tells us why he believes the biotech boom still has plenty...
BDSI: 14.92 (+0.93), GILD: 101.90 (+1.10), RTRX: 13.92 (+0.44), ASPX: 65.76 (+2.76)
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 23, 12:32PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LGCY: 13.35 (+0.51), QADB: 17.59 (+0.05), EOPN: 8.55 (-0.01), QADA: 20.36 (+0.14), IMKTA: 42.26 (-0.18), CHUY: 22.04 (-0.35), OTIC: 31.14 (+0.13), SNMX: 5.92 (+0.26), DWCH: 6.26 (-0.18), EGLT: 10.60 (+0.58), RTRX: 13.92 (+0.44), INFN: 17.56 (-0.10), Z: 106.50 (+1.75)
Retrophin provides 2014 revenue guidance
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 8:53AM CST
RTRX: 13.92 (+0.44)
Retrophin Announces Acquisition of Exclusive Right to Purchase Cholic Acid from Asklepion Pharmaceuticals
Business Wire - Mon Jan 12, 7:02AM CST
Retrophin, Inc. (NASDAQ:RTRX) and Asklepion Pharmaceuticals, LLC, a privately held rare disease pharmaceutical development company, today announced the signing of a definitive agreement under which Retrophin has acquired the exclusive right to purchase from Asklepion, all worldwide rights, titles, and ownership of cholic acid for the treatment of bile acid synthesis defects, if approved by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, Retrophin will pay Asklepion an upfront payment of $5 million and up to $73 million in milestones based on approval and net product sales, plus tiered royalties on future net sales of cholic acid. Retrophin has secured a line of credit from current lenders to cover necessary payments.
RTRX: 13.92 (+0.44)
Ligand wins US FDA's orphan drug designation for Sparsentan for focal segmental glomerulosclerosis
M2 - Mon Jan 12, 6:28AM CST
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) disclosed on Friday the receipt of orphan drug designation for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).
RTRX: 13.92 (+0.44), LGND: 55.91 (-0.35)
The Shuman Law Firm Investigates Retrophin, Inc.
Business Wire - Fri Jan 09, 7:00PM CST
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Retrophin, Inc. ("Retrophin" or the "Company"
(Nasdaq: RTRX). Retrophin is a New York, NY-based company that develops therapies for the treatment of serious, catastrophic or rare diseases. RTRX: 13.92 (+0.44)
Ryan & Maniskas, LLP Announces Investigation of Retrophin, Inc.
PR Newswire - Fri Jan 09, 6:35PM CST
Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Retrophin, Inc. ("Retrophin" or the "Company"
(NASDAQ: RTRX). RTRX: 13.92 (+0.44)
Sparsentan tagged an Orphan Drug for rare nephropathy
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 9:47AM CST
RTRX: 13.92 (+0.44), LGND: 55.91 (-0.35)
Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
Business Wire - Fri Jan 09, 9:15AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Retrophin, Inc. (NASDAQ:RTRX) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).
RTRX: 13.92 (+0.44), LGND: 55.91 (-0.35)
Retrophin Provides Corporate Update
Business Wire - Fri Jan 09, 7:00AM CST
--Sparsentan for the treatment of FSGS receives orphan drug designation from FDA
RTRX: 13.92 (+0.44)
Updated: Harwood Feffer LLP Announces Investigation of Retrophin, Inc.
PR Newswire - Thu Jan 08, 7:10PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Retrophin, Inc. ("Retrophin" or the "Company"
(NASDAQ: RTRX), concerning whether the board has breached its fiduciary duties to shareholders. RTRX: 13.92 (+0.44)
Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Jan 06, 4:00PM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced the grant of inducement awards to 14 employees that occurred on January 5, 2015. The awards were granted as an inducement material to each such employee's entering into employment with Retrophin pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The 14 employees were granted inducement awards consisting of stock options to purchase an aggregate of 355,000 shares of Retrophin common stock and 40,000 shares of restricted common stock. The stock options and restricted common stock vest in equal quarterly installments over a period of three years. The stock options are nonstatutory stock options and have an exercise price equal to $13.02 per share, the fair market value of Retrophin's common stock on the date of grant.
RTRX: 13.92 (+0.44)
Commit To Buy Retrophin At $10, Earn 28.9% Annualized Using Options
StockOptionsChannel.com - Wed Dec 24, 11:18AM CST
Investors considering a purchase of Retrophin, Inc. shares, but cautious about paying the going market price of $12.82/share, might benefit from considering selling puts among the alternative strategies at their disposal.
RTRX: 13.92 (+0.44)
Attention Retrophin, Inc. (RTRX) Shareholders: Retrophin Mislead Investors According to a Newly Filed Class Action
GlobeNewswire - Mon Dec 22, 7:18PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Retrophin, Inc. (Nasdaq:RTRX) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between November 13, 2013 and September 30, 2014. Retrophin is a biopharmaceutical company that develops, acquires, and commercializes therapies for the treatment of serious, catastrophic, and rare diseases.
RTRX: 13.92 (+0.44)
The Winners for Best and Worst Biotech CEOs of 2014 Are...
at The Street - Thu Dec 18, 9:01AM CST
Congrats to David Schenkhein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
BLUE: 90.70 (+0.93), RTRX: 13.92 (+0.44), AGIO: 118.55 (+0.11)
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Retrophin, Inc. and a Lead Plaintiff Deadline of December 19, 2014 -- RTRX
GlobeNewswire - Tue Dec 16, 3:54PM CST
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Retrophin, Inc. ("Retrophin" or the "Company"
(Nasdaq:RTRX) securities between March 27, 2014 and September 30, 2014. RTRX: 13.92 (+0.44)
Retrophin Announces Addition to the NASDAQ Biotechnology Index
Business Wire - Tue Dec 16, 7:00AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to market open on Monday, December 22, 2014.
RTRX: 13.92 (+0.44)
